{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:39:53Z","timestamp":1792460393880,"version":"4.5.0"},"reference-count":88,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T00:00:00Z","timestamp":1698969600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019671","name":"Fondation Pour l'Audition","doi-asserted-by":"publisher","award":["FPA IDA10"],"award-info":[{"award-number":["FPA IDA10"]}],"id":[{"id":"10.13039\/100019671","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.therap.2023.10.011","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T22:59:58Z","timestamp":1698793198000},"page":"283-295","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Drug-induced hearing loss: Listening to the latest advances"],"prefix":"10.1016","volume":"79","author":[{"given":"Pierre","family":"Reynard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung","family":"Thai-Van","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2023.10.011_bib0445","doi-asserted-by":"crossref","first-page":"108783","DOI":"10.1016\/j.heares.2023.108783","article-title":"Role of mitochondrial dysfunction and oxidative stress in sensorineural hearing loss","volume":"434","author":"Tan","year":"2023","journal-title":"Hear Res"},{"key":"10.1016\/j.therap.2023.10.011_bib0450","doi-asserted-by":"crossref","first-page":"e00970","DOI":"10.1002\/prp2.970","article-title":"Hearing loss: the final frontier of pharmacology","volume":"10","author":"Foster","year":"2022","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.therap.2023.10.011_bib0455","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1152\/physrev.00053.2017","article-title":"Toward cochlear therapies","volume":"98","author":"Wang","year":"2018","journal-title":"Physiol Rev"},{"key":"10.1016\/j.therap.2023.10.011_bib0460","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.mrfmmm.2018.03.003","article-title":"Mitochondrial mutations associated with hearing and balance disorders","volume":"810","author":"Ibrahim","year":"2018","journal-title":"Mutat Res"},{"key":"10.1016\/j.therap.2023.10.011_bib0465","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.heares.2013.01.006","article-title":"The mitochondrion: a perpetrator of acquired hearing loss","volume":"303","author":"B\u00f6ttger","year":"2013","journal-title":"Hear Res"},{"key":"10.1016\/j.therap.2023.10.011_bib0470","article-title":"Cochlear detoxification: role of alpha class glutathione transferases in protection against oxidative lipid damage, ototoxicity, and cochlear aging","volume":"15","author":"Someya","year":"2021","journal-title":"Hear Res"},{"key":"10.1016\/j.therap.2023.10.011_bib0475","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1097\/MPH.0000000000001637","article-title":"Platinum-drugs ototoxicity in pediatric patients with brain tumors: a 10-year review","volume":"42","author":"Rabi\u00e7o-Costa","year":"2020","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.therap.2023.10.011_bib0480","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s00106-019-0663-1","article-title":"Pharmacological intervention in the field of ototoxicity","volume":"67","author":"Laurell","year":"2019","journal-title":"HNO"},{"key":"10.1016\/j.therap.2023.10.011_bib0485","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/fcp.12533","article-title":"Drug-induced hearing loss: a case\/non-case study in the French pharmacovigilance database","volume":"34","author":"Favreli\u00e8re","year":"2020","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2023.10.011_bib0490","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1002\/phar.2478","article-title":"Drug-induced ototoxicity: a comprehensive review and reference guide","volume":"40","author":"Rizk","year":"2020","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.therap.2023.10.011_bib0495","doi-asserted-by":"crossref","first-page":"14045","DOI":"10.1038\/s41598-021-93522-z","article-title":"Detection of unknown ototoxic adverse drug reactions: an electronic healthcare record-based longitudinal nationwide cohort analysis","volume":"11","author":"Lee","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.therap.2023.10.011_bib0500","doi-asserted-by":"crossref","first-page":"167","DOI":"10.5152\/iao.2022.21416","article-title":"Ototoxicity of immunosuppressant drugs: a systematic review","volume":"18","author":"Franz","year":"2022","journal-title":"J Int Adv Otol"},{"key":"10.1016\/j.therap.2023.10.011_bib0505","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/lt.21385","article-title":"Audiometric changes in patients undergoing liver transplantation using distinct immunosuppressive protocols","volume":"14","author":"Fortes","year":"2008","journal-title":"Liver Transpl"},{"key":"10.1016\/j.therap.2023.10.011_bib0510","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1432-2277.2006.00317.x","article-title":"Sudden hearing loss associated with tacrolimus in a liver transplant recipient","volume":"19","author":"Norman","year":"2006","journal-title":"Transpl Int"},{"key":"10.1016\/j.therap.2023.10.011_bib0515","doi-asserted-by":"crossref","first-page":"562","DOI":"10.6002\/ect.2012.0241","article-title":"Sudden hearing loss associated with tacrolimus after pediatric renal transplant","volume":"11","author":"Gulleroglu","year":"2013","journal-title":"Exp Clin Transplant"},{"key":"10.1016\/j.therap.2023.10.011_bib0520","first-page":"183","article-title":"Sensorineural hearing loss in ankylosing spondylitis treated with TNF blockers","volume":"6","author":"Savastano","year":"2010","journal-title":"B-ENT"},{"key":"10.1016\/j.therap.2023.10.011_bib0525","doi-asserted-by":"crossref","first-page":"102117","DOI":"10.1016\/j.tmaid.2021.102117","article-title":"Ototoxic hearing loss from antimalarials: a systematic narrative review","volume":"43","author":"Dillard","year":"2021","journal-title":"Travel Med Infect Dis"},{"key":"10.1016\/j.therap.2023.10.011_bib0530","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.bjorl.2021.02.008","article-title":"Ototoxic effects of antineoplastic drugs: a systematic review","volume":"88","author":"Patatt","year":"2022","journal-title":"Braz J Otorhinolaryngol"},{"key":"10.1016\/j.therap.2023.10.011_bib0535","first-page":"256","article-title":"Ototoxicity\u00a0in Nigeria: why it persists","volume":"93","author":"Kokong","year":"2014","journal-title":"Ear Nose Throat J"},{"key":"10.1016\/j.therap.2023.10.011_bib0540","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3389\/fpubh.2020.00252","article-title":"Clinical implications of chloroquine and hydroxychloroquine ototoxicity for COVID-19 treatment: a mini-review","volume":"8","author":"Prayuenyong","year":"2020","journal-title":"Front Public Health"},{"key":"10.1016\/j.therap.2023.10.011_bib0545","doi-asserted-by":"crossref","first-page":"102640","DOI":"10.1016\/j.amjoto.2020.102640","article-title":"Chloroquine and hydroxychloroquine ototoxicity; potential implications for SARS-CoV-2 treatment. A brief review of the literature","volume":"42","author":"De Luca","year":"2021","journal-title":"Am J Otolaryngol"},{"key":"10.1016\/j.therap.2023.10.011_bib0550","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","volume":"14","author":"Gao","year":"2020","journal-title":"Biosci Trends"},{"key":"10.1016\/j.therap.2023.10.011_bib0555","doi-asserted-by":"crossref","DOI":"10.1177\/20587384211027373","article-title":"SARS-CoV-2 (COVID-19) and audio-vestibular disorders","volume":"35","author":"Fancello","year":"2021","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.therap.2023.10.011_bib0560","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/ijpp.12670","article-title":"Sensorineural hearing loss with macrolide antibiotics exposure: a meta-analysis of the association","volume":"29","author":"Alsowaida","year":"2020","journal-title":"Int J Pharm Pract"},{"key":"10.1016\/j.therap.2023.10.011_bib0565","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/lary.26799","article-title":"Macrolide-associated sensorineural hearing loss: a systematic review","volume":"128","author":"Ikeda","year":"2018","journal-title":"Laryngoscope"},{"key":"10.1016\/j.therap.2023.10.011_bib0570","doi-asserted-by":"crossref","first-page":"725566","DOI":"10.3389\/fneur.2021.725566","article-title":"detecting novel ototoxins and potentiation of ototoxicity by disease settings","volume":"12","author":"Coffin","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.therap.2023.10.011_bib0575","doi-asserted-by":"crossref","first-page":"e45263","DOI":"10.2196\/45263","article-title":"Safety signal generation for sudden sensorineural hearing loss following messenger RNA COVID-19 vaccination: postmarketing surveillance using the french pharmacovigilance spontaneous reporting database","volume":"9","author":"Thai-Van","year":"2023","journal-title":"JMIR Public Health Surveill"},{"key":"10.1016\/j.therap.2023.10.011_bib0580","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.bjorl.2015.08.011","article-title":"High frequency hearing thresholds and product distortion otoacoustic emissions in cystic fibrosis patients","volume":"81","author":"Geyer","year":"2015","journal-title":"Braz J Otorhinolaryngol"},{"key":"10.1016\/j.therap.2023.10.011_bib0585","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/cpt.603","article-title":"Drug-induced ototoxicity: mechanisms, pharmacogenetics, and protective strategies","volume":"101","author":"Lanvers-Kaminsky","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.therap.2023.10.011_bib0590","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/pds.4125","article-title":"Differences in VigiBase\u00ae reporting of aminoglycoside and capreomycin-suspected ototoxicity during tuberculosis treatment","volume":"26","author":"Sagwa","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.therap.2023.10.011_bib0595","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jinf.2021.05.010","article-title":"Prevalence of aminoglycoside-induced hearing loss in drug-resistant tuberculosis patients: a systematic review","volume":"83","author":"Dillard","year":"2021","journal-title":"J Infect"},{"key":"10.1016\/j.therap.2023.10.011_bib0600","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s00204-019-02407-8","article-title":"Adverse outcome pathway for aminoglycoside ototoxicity in drug-resistant tuberculosis treatment","volume":"93","author":"Hong","year":"2019","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.therap.2023.10.011_bib0605","doi-asserted-by":"crossref","first-page":"e14036","DOI":"10.2196\/14036","article-title":"An ototoxicity grading system within a mobile app (OtoCalc) for a resource-limited setting to guide grading and management of drug-induced hearing loss in patients with drug-resistant tuberculosis: prospective, cross-sectional case series","volume":"8","author":"Hollander","year":"2020","journal-title":"JMIR Mhealth Uhealth"},{"key":"10.1016\/j.therap.2023.10.011_bib0610","doi-asserted-by":"crossref","first-page":"e2739","DOI":"10.1371\/journal.pntd.0002739","article-title":"Long term streptomycin toxicity in the treatment of Buruli Ulcer: follow-up of participants in the BURULICO drug trial","volume":"8","author":"Klis","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.therap.2023.10.011_bib0615","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.4102\/safp.v63i1.5187","article-title":"Ototoxicity: a review of South African studies","volume":"63","author":"Moodley","year":"2021","journal-title":"S Afr Fam Pract"},{"key":"10.1016\/j.therap.2023.10.011_bib0620","doi-asserted-by":"crossref","first-page":"a033548","DOI":"10.1101\/cshperspect.a033548","article-title":"Aminoglycoside- and cisplatin-induced ototoxicity: mechanisms and otoprotective strategies","volume":"9","author":"Kros","year":"2019","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.therap.2023.10.011_bib0625","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1044\/2021_AJA-21-00006","article-title":"Mechanisms of aminoglycoside- and cisplatin-induced ototoxicity","volume":"30","author":"Steyger","year":"2021","journal-title":"Am J Audiol"},{"key":"10.1016\/j.therap.2023.10.011_bib0630","doi-asserted-by":"crossref","first-page":"1782659","DOI":"10.1155\/2020\/1782659","article-title":"Liproxstatin-1 protects hair cell-like HEI-OC1 cells and cochlear hair cells against neomycin ototoxicity","volume":"2020","author":"Zheng","year":"2020","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.therap.2023.10.011_bib0635","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/QCO.0000000000000263","article-title":"Vancomycin toxicity in neonates: a review of the evidence","volume":"29","author":"Lestner","year":"2016","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.therap.2023.10.011_bib0640","doi-asserted-by":"crossref","first-page":"1782659","DOI":"10.1155\/2020\/1782659","article-title":"Liproxstatin-1 protects hair cell-like HEI-OC1 cells and cochlear hair cells against neomycin ototoxicity","volume":"2020","author":"Zheng","year":"2020","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.therap.2023.10.011_bib0645","first-page":"5684","article-title":"Pharmacogenetic screening of A1555G and C1494T mitochondrial mutations and the use of ototoxic drugs among Jordanians","volume":"25","author":"Yehya","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.therap.2023.10.011_bib0650","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/QCO.0000000000000263","article-title":"Vancomycin toxicity in neonates: a review of the evidence","volume":"29","author":"Lestner","year":"2016","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.therap.2023.10.011_bib0655","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1093\/jac\/dkab232","article-title":"Macrolide-associated\u00a0ototoxicity: a cross-sectional and longitudinal study to assess the association of macrolide use with tinnitus and\u00a0hearing\u00a0loss","volume":"76","author":"Vanoverschelde","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.therap.2023.10.011_bib0660","doi-asserted-by":"crossref","first-page":"e230251","DOI":"10.1136\/bcr-2019-230251","article-title":"Ototoxicity, a rare but reversible adverse effect of a commonly used antimicrobial agent","volume":"12","author":"Singh","year":"2019","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.therap.2023.10.011_bib0665","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejpb.2021.03.008","article-title":"Cisplatin-induced ototoxicity: updates on molecular mechanisms and otoprotective strategies","volume":"163","author":"Tang","year":"2021","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.therap.2023.10.011_bib0670","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/S1470-2045(18)30858-1","volume":"20","author":"Clemens","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.therap.2023.10.011_bib0675","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejca.2016.09.023","article-title":"DCOG-LATER, The Netherlands. Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: a DCOG late-effects study","volume":"69","author":"Clemens","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.therap.2023.10.011_bib0680","article-title":"Platinum-induced hearing loss after treatment for childhood cancer","volume":"2016","author":"Van\u00a0As","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.therap.2023.10.011_bib0685","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1097\/CAD.0b013e3283650bda","article-title":"Platinum compounds in children with cancer: toxicity and clinical management","volume":"24","author":"Ruggiero","year":"2013","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.therap.2023.10.011_bib0690","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1093\/neuonc\/not241","article-title":"Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma","volume":"16","author":"Gurney","year":"2014","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.therap.2023.10.011_bib0695","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s40272-022-00550-x","article-title":"Sodium thiosulfate: pediatric first approval","volume":"25","author":"Dhillon","year":"2023","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.therap.2023.10.011_bib0700","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1159\/000442435","article-title":"Audiological monitoring in children treated with platinum chemotherapy","volume":"21","author":"Fetoni","year":"2016","journal-title":"Audiol Neurootol"},{"key":"10.1016\/j.therap.2023.10.011_bib0705","doi-asserted-by":"crossref","first-page":"114045","DOI":"10.1016\/j.biopha.2022.114045","article-title":"Cisplatin-induced\u00a0ototoxicity: from signaling network to therapeutic targets","volume":"157","author":"Wang","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.therap.2023.10.011_bib0710","doi-asserted-by":"crossref","first-page":"4909237","DOI":"10.1155\/2021\/4909237","article-title":"Hair cell protection from ototoxic drugs","volume":"2021","author":"Wu","year":"2021","journal-title":"Neural Plast"},{"key":"10.1016\/j.therap.2023.10.011_bib0715","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1158\/1078-0432.CCR-16-2809","article-title":"Variants in WFS1 and other mendelian deafness genes are associated with cisplatin-associated ototoxicity","volume":"23","author":"Wheeler","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.therap.2023.10.011_bib0720","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1007\/s12094-018-1964-7","article-title":"Contribution of the GSTP1 c.313A>G variant to hearing loss risk in patients exposed to platin chemotherapy during childhood","volume":"21","author":"Liberman","year":"2019","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.therap.2023.10.011_bib0725","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ejca.2020.07.019","article-title":"PanCareLIFE consortium. Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: results of the European PanCareLIFE cohort study","volume":"138","author":"Langer","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.therap.2023.10.011_bib0730","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/gerona\/glz166","article-title":"The contribution of ototoxic medications to hearing loss among older adults","volume":"75","author":"Joo","year":"2020","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.therap.2023.10.011_bib0735","doi-asserted-by":"crossref","first-page":"108626","DOI":"10.1016\/j.heares.2022.108626","article-title":"Structural changes in the human stria vascularis induced by aminoglycosides and loop diuretics","volume":"426","author":"Wright","year":"2022","journal-title":"Hear Res"},{"key":"10.1016\/j.therap.2023.10.011_bib0740","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejca.2017.09.033","article-title":"COAST (Cisplatin ototoxicity attenuated by aspirin trial): a phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss","volume":"87","author":"Crabb","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.therap.2023.10.011_bib0745","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/JXX.0000000000000011","article-title":"Prevalence of\u00a0ototoxic\u00a0medication use among older adults in Beaver Dam, Wisconsin","volume":"30","author":"Joo","year":"2018","journal-title":"J Am Assoc Nurse Pract"},{"key":"10.1016\/j.therap.2023.10.011_bib0750","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1159\/000521965","article-title":"Hearing\u00a0and vestibular\u00a0loss\u00a0with misuse of opioids and illicit\u00a0drugs: a review of the literature","volume":"27","author":"Hughes","year":"2022","journal-title":"Audiol Neurootol"},{"key":"10.1016\/j.therap.2023.10.011_bib0755","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1080\/14740338.2017.1372420","article-title":"The auditory and vestibular toxicities induced by antiepileptic\u00a0drugs","volume":"16","author":"Hamed","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.therap.2023.10.011_bib0760","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ijporl.2018.07.035","article-title":"In utero\u00a0drug\u00a0exposure and\u00a0hearing\u00a0impairment in 2-year-old children A case-control study using the EFEMERIS database","volume":"113","author":"Foch","year":"2018","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"10.1016\/j.therap.2023.10.011_bib0765","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1124\/molpharm.121.000274","article-title":"Current understanding of membrane transporters as regulators or targets for cisplatin-induced hearing loss","volume":"100","author":"Pasquariello","year":"2021","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.therap.2023.10.011_bib0770","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S2352-4642(19)30115-4","article-title":"Interventions for cisplatin-induced hearing loss in children and adolescents with cancer","volume":"3","author":"Freyer","year":"2019","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.therap.2023.10.011_bib0775","doi-asserted-by":"crossref","first-page":"5512","DOI":"10.1021\/acs.jmedchem.7b01653","article-title":"Progress in the development of preventative drugs for cisplatin-induced hearing loss","volume":"61","author":"Hazlitt","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.therap.2023.10.011_bib0780","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1093\/neuonc\/not241","article-title":"Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma","volume":"16","author":"Gurney","year":"2014","journal-title":"Neuro Oncol"},{"issue":"Suppl.\u00a04","key":"10.1016\/j.therap.2023.10.011_bib0785","first-page":"S67","article-title":"Protection for medication-induced hearing loss: the state of the science","volume":"57","author":"Hammill","year":"2018","journal-title":"Int J Audiol"},{"key":"10.1016\/j.therap.2023.10.011_bib0790","doi-asserted-by":"crossref","first-page":"108209","DOI":"10.1016\/j.heares.2021.108209","article-title":"Development of ebselen for the treatment of sensorineural hearing loss and tinnitus","volume":"413","author":"Kil","year":"2022","journal-title":"Hear Res"},{"key":"10.1016\/j.therap.2023.10.011_bib0795","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3390\/nu12040947","article-title":"Protective mechanisms of avocado oil extract against ototoxicity","volume":"12","author":"Pham","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.therap.2023.10.011_bib0800","doi-asserted-by":"crossref","first-page":"5511010","DOI":"10.1155\/2021\/5511010","article-title":"Autophagy: a novel horizon for hair cell protection","volume":"2021","author":"Liu","year":"2021","journal-title":"Neural Plast"},{"key":"10.1016\/j.therap.2023.10.011_bib0805","doi-asserted-by":"crossref","first-page":"e2921","DOI":"10.1038\/cddis.2017.314","article-title":"Epigallocatechin-3-gallate, a prototypic chemopreventative agent for protection against cisplatin-based ototoxicity","volume":"8","author":"Borse","year":"2017","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.therap.2023.10.011_bib0810","doi-asserted-by":"crossref","first-page":"108430","DOI":"10.1016\/j.heares.2022.108430","article-title":"A combinatorial approach to protect sensory tissue against cisplatin-induced ototoxicity","volume":"415","author":"Febles","year":"2022","journal-title":"Hear Res"},{"key":"10.1016\/j.therap.2023.10.011_bib0815","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1179\/1754762812Y.0000000020","article-title":"Cochlear implantation in patients deafened by\u00a0ototoxic\u00a0drugs","volume":"14","author":"Nichani","year":"2013","journal-title":"Cochlear Implants Int"},{"key":"10.1016\/j.therap.2023.10.011_bib0820","doi-asserted-by":"crossref","first-page":"13","DOI":"10.21873\/invivo.12227","article-title":"Therapeutic application of mesenchymal stem cells for cochlear regeneration","volume":"35","author":"Maharajan","year":"2021","journal-title":"In Vivo"},{"key":"10.1016\/j.therap.2023.10.011_bib0825","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.3390\/molecules23102507","article-title":"Gene delivery into the inner ear and its clinical implications for hearing and balance","volume":"23","author":"Kanzaki","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.therap.2023.10.011_bib0830","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/13543776.2017.1252751","article-title":"Recent advances in therapeutics and\u00a0drug\u00a0delivery for the treatment of inner ear diseases: a patent review (2011-2015)","volume":"27","author":"Nguyen","year":"2017","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.therap.2023.10.011_bib0835","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1080\/21691401.2019.1573182","article-title":"Nanoparticle-based drug delivery in the inner ear: current challenges, limitations and opportunities","volume":"47","author":"Mittal","year":"2019","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"10.1016\/j.therap.2023.10.011_bib0840","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s10637-020-00918-1","article-title":"Phase 1 study to evaluate safety, tolerability and pharmacokinetics of a novel intra-tympanic administered thiosulfate to prevent cisplatin-induced hearing loss in cancer patients","volume":"38","author":"Viglietta","year":"2020","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.therap.2023.10.011_bib0845","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1159\/000442435","article-title":"Audiological monitoring in children treated with platinum chemotherapy","volume":"21","author":"Fetoni","year":"2016","journal-title":"Audiol Neurootol"},{"key":"10.1016\/j.therap.2023.10.011_bib0850","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1017\/S0022215121000025","article-title":"An audit of UK audiological practice in specialist paediatric oncology centres regarding hearing assessment of children at risk of ototoxicity due to chemotherapy","volume":"135","author":"Brown","year":"2021","journal-title":"J Laryngol Otol"},{"key":"10.1016\/j.therap.2023.10.011_bib0855","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000526403","article-title":"Applications of the grading scales for the detection of\u00a0ototoxicity\u00a0in children after treatment of neuroblastoma and extracranial germinal tumor","volume":"28","author":"Polski","year":"2023","journal-title":"Audiol Neurootol"},{"key":"10.1016\/j.therap.2023.10.011_bib0860","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/AUD.0000000000000464","article-title":"Chirp-evoked otoacoustic emissions and middle ear absorbance for monitoring\u00a0ototoxicity\u00a0in cystic fibrosis patients","volume":"39","author":"Garinis","year":"2018","journal-title":"Ear Hear"},{"key":"10.1016\/j.therap.2023.10.011_bib0865","series-title":"American Speech-Language-Hearing Association","year":"2023"},{"key":"10.1016\/j.therap.2023.10.011_bib0870","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1200\/JCO.2016.66.8822","article-title":"Comprehensive audiometric analysis of hearing impairment and tinnitus after cisplatin-based chemotherapy in survivors of adult-onset cancer","volume":"34","author":"Frisina","year":"2016","journal-title":"J Clin Oncol"},{"issue":"Suppl. 4","key":"10.1016\/j.therap.2023.10.011_bib0875","first-page":"S41","article-title":"Monitoring neonates for ototoxicity","volume":"57","author":"Garinis","year":"2018","journal-title":"Int J Audiol"},{"key":"10.1016\/j.therap.2023.10.011_bib0880","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.mehy.2015.04.015","article-title":"Prestin as a biochemical marker for early detection of acquired sensorineural hearing loss","volume":"85","author":"Parham","year":"2015","journal-title":"Med Hypotheses"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595723001774?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595723001774?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T19:59:06Z","timestamp":1711655946000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595723001774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":88,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0040595723001774"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2023.10.011","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-induced hearing loss: Listening to the latest advances","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2023.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique.","name":"copyright","label":"Copyright"}]}}